{"id":2548,"date":"2018-02-14T23:35:33","date_gmt":"2018-02-14T18:05:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2548"},"modified":"2025-05-06T18:12:03","modified_gmt":"2025-05-06T12:42:03","slug":"snippet-4","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-4","title":{"rendered":"Gilead Sciences Introduces Sovaldi: A Potent Hepatitis C Treatment"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Gilead Sciences<\/strong>\u00a0has recently launched a highly effective hepatitis C drug <strong>Sovaldi<\/strong> at a whopping price of <strong>USD 84,000<\/strong> per treatment course at the same time when \u2018<strong>How to price a cure<\/strong>\u2019 discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it&#8217;s very cost-effective and they don&#8217;t have to do any discount scheme until any other competitor does the same. Gilead always made a clear stand and has never apologized for how it priced Sovaldi or its subsequent hepatitis C drugs. Gilead is again facing backlash and has started a new debate after pricing its newly approved CAR-T therapy <strong>Yescarta<\/strong> at <strong>USD 373,000<\/strong> per patient. However, Sovaldi is no longer a hot topic it once was due to the declining hepatitis C market revenues. With the entry of new one-time gene therapies in the market, the question of how to price a cure remains a topic of interest for almost everyone related to the pharmaceutical industry. <strong>Spark Therapeutics<\/strong> recently launched a gene therapy treatment with a price tag of <strong>USD 850,000<\/strong>, the company aims to pair it with contracts that tie net price to the treatment&#8217;s efficacy at certain points in time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment course at the same time when \u2018How to price a cure\u2019 discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it&#8217;s very cost-effective and they don&#8217;t [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2549,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[810,204,1393,1394,381,1261,1196,965,543,16932],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-2548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-car-t","tag-delveinsight","tag-gilead-sciences","tag-hepatitis-c","tag-market-research","tag-pharma-consulting","tag-pharma-research","tag-sovaldi","tag-spark-therapeutics","tag-yescarta","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sovaldi Treatment For Hepatitis C Treatment<\/title>\n<meta name=\"description\" content=\"Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-4\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sovaldi Treatment For Hepatitis C Treatment\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-4\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-14T18:05:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T12:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"849\" \/>\n\t<meta property=\"og:image:height\" content=\"493\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sovaldi Treatment For Hepatitis C Treatment","description":"Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-4","og_locale":"en_US","og_type":"article","og_title":"Sovaldi Treatment For Hepatitis C Treatment","og_description":"Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment...","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-4","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-14T18:05:33+00:00","article_modified_time":"2025-05-06T12:42:03+00:00","og_image":[{"width":849,"height":493,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-4","url":"https:\/\/www.delveinsight.com\/blog\/snippet-4","name":"Sovaldi Treatment For Hepatitis C Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-4#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-4#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO.jpg","datePublished":"2018-02-14T18:05:33+00:00","dateModified":"2025-05-06T12:42:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead Sciences\u00a0has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-4"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-4#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO.jpg","width":849,"height":493},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/02\/09021226\/849x493q70GroundUp-sofosbuvir-MAIN-PHOTO-300x174.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">gilead sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">hepatitis c<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Sovaldi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spark therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Yescarta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">gilead sciences<\/span>","<span class=\"advgb-post-tax-term\">hepatitis c<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">Sovaldi<\/span>","<span class=\"advgb-post-tax-term\">Spark therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Yescarta<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Feb 14, 2018","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Feb 14, 2018 11:35 pm","modified":"Updated on May 6, 2025 6:12 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2548"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2548\/revisions"}],"predecessor-version":[{"id":28297,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2548\/revisions\/28297"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2549"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2548"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2548"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}